Stroke Prevention in Nonvalvular Atrial Fibrillation A Stakeholder Perspective

被引:47
|
作者
Alkhouli, Mohamad [1 ,2 ]
Noseworthy, Peter A. [1 ,3 ]
Rihal, Charanjit S. [3 ]
Holmes, David R., Jr. [1 ]
机构
[1] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA
[2] West Virginia Univ, Dept Med, Div Cardiovasc Dis, Morgantown, WV USA
[3] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA
关键词
atrial fibrillation; left atrial appendage; non-vitamin K antagonist oral anticoagulant; oral anticoagulation; risk reduction; stroke; QUALITY-OF-LIFE; ANTAGONIST ORAL ANTICOAGULANTS; RANDOMIZED CONTROLLED-TRIALS; SHARED DECISION-MAKING; VITAMIN-K ANTAGONISTS; APPENDAGE CLOSURE; COST-EFFECTIVENESS; ISCHEMIC-STROKE; NETWORK METAANALYSIS; WARFARIN THERAPY;
D O I
10.1016/j.jacc.2018.04.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ischemic stroke in patients with atrial fibrillation is associated with substantial morbidity and mortality. The growing epidemic of atrial fibrillation worldwide has raised concerns about the dire need for effective stroke prevention systems in these patients. Fortunately, the last decade has witnessed a plethora of data on novel stroke prevention methods in patients with nonvalvular atrial fibrillation. However, optimal selection and effective implementation of these preventative strategies require an integrative approach that takes into account not only the available clinical data but also the perspective of each of the stakeholders involved (patient, physician, and society). The goal of this review was to discuss the contemporary issues surrounding stroke prevention in atrial fibrillation from the perspective of these 3 major stakeholders. (C) 2018 by the American College of Cardiology Foundation.
引用
收藏
页码:2790 / 2801
页数:12
相关论文
共 50 条
  • [41] DURATION OF NONVALVULAR ATRIAL-FIBRILLATION AND STROKE
    WOLF, PA
    KANNEL, WB
    STROKE, 1983, 14 (05) : 827 - 827
  • [42] ISCHEMIC STROKE AND NONVALVULAR ATRIAL-FIBRILLATION
    HORNIG, CR
    WILL, R
    DORNDORF, W
    AKTUELLE NEUROLOGIE, 1989, 16 (06) : 195 - 200
  • [43] STUDY ON PREVENTION OF EMBOLISM IN NONVALVULAR ATRIAL FIBRILLATION
    Wang Yue-Xi
    Zhang Ying-Jun
    HEART, 2012, 98 : E263 - E264
  • [45] Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation patient considerations
    Ahrens, Ingo
    Bode, Christoph
    JOURNAL OF BLOOD MEDICINE, 2014, 5 : 25 - 30
  • [46] Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
    Lin, Yi-Pin
    Tan, Teng-Yeow
    MEDICINE, 2015, 94 (38)
  • [47] Anticoagulation Protocol for Secondary Prevention of Acute Ischemic Stroke Associated with Nonvalvular Atrial Fibrillation
    Kimura, Teruo
    Tucker, Adam
    Nakagaki, Atsushi
    Sugimura, Toshihide
    Fukuda, Shin
    Katsuno, Makoto
    Fujita, Tsutomu
    Izumi, Naoto
    Suzuki, Nozomi
    Sako, Kazuhiro
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2021, 30 (08):
  • [48] Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
    Lam, Sum
    CARDIOLOGY IN REVIEW, 2013, 21 (04) : 207 - 212
  • [49] Warfarin vs aspirin for prevention of stroke in nonvalvular atrial fibrillation: Meta-analysis
    Benavente, O
    Hart, RG
    STROKE, 1999, 30 (01) : 241 - 241
  • [50] Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation
    Helms T.M.
    Silber S.
    Schäfer A.
    Masuhr F.
    Palm F.
    Darius H.
    Schrör K.
    Bänsch D.
    Bramlage P.
    Hankowitz J.
    Karle C.A.
    Stargardt T.
    Weil J.
    Geller J.C.
    Herzschrittmachertherapie + Elektrophysiologie, 2016, 27 (3) : 295 - 306